A Phase 3 clinical trial has demonstrated that patients with advanced (Stage 3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, combined with...

City of Hope physicians will present research on promising treatments for blood, prostate and other cancers, as well as studies on genetic testing for hereditary cancers and on reducing heart...

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced it would present research on promising treatments for bladder and blood cancers...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   Positive Phase 1b data recently presented at ASCO 2021 show clinical benefit of CBM588 plus checkpoint inhibitor therapy in patients with metastatic renal cell...

Over the first week in June, premier oncology researchers from City of Hope gathered virtually at the American Society of Clinical Oncology Annual meeting with experts from around the world...

DUARTE, Calif. — A first-ever inhibitor of a cancer gene found in some lung, colorectal and other cancers and the effectiveness of chimeric antigen receptor (CAR) T cell therapy for...

A targeted therapy for colorectal cancer and an immunotherapy drug for head and neck cancer are just some of the innovative treatments City of Hope doctors presented at this year’s...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   City of Hope experts are available to comment on research presented at the American Society of Clinical Oncology May 31 – June 4 in...

CONTACT Wendy Lawton Communications Manager SWOG Cancer Research Network 503-348-8675 lawtonw@ohsu.edu   Zen Vuong Senior Media Relations Specialist City of Hope 626-409-9367 zvuong@coh.org     DUARTE, Calif. – In a SWOG...

Joanne Mortimer, M.D. Joanne Mortimer, M.D., was one of just 25 oncologists nationwide named a fellow of the American Society of Clinical Oncology for 2019. Launched in 2007 as...